Foundayo (orforglipron)
Eli Lilly (LLY)
ApprovedApr 1, 2026
Marketer take
An oral, non-peptide GLP-1 for weight management that competes on convenience with injectables like Wegovy and Zepbound and pushes obesity care further into primary care.
- Sponsor company
- Eli Lilly (LLY)
- Indication
- To reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity
- Therapeutic area
- Obesity, Metabolic
- Event
- FDA approval
- Date
- Apr 1, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?